What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery are his primary areas of study.
His Gastroenterology research extends to Internal medicine, which is thematically connected.
His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Epidermal growth factor receptor and Regimen.
His research integrates issues of Docetaxel, Adverse effect, Proportional hazards model and Phases of clinical research in his study of Lung cancer.
His biological study spans a wide range of topics, including T-cell lymphoma, Pharmacokinetics and Toxicity.
His Gemcitabine research focuses on subjects like Necitumumab, which are linked to Deoxycytidine.
His most cited work include:
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer (2559 citations)
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2085 citations)
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial (672 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His Internal medicine study which covers Gastroenterology that intersects with Neutropenia.
His Oncology study combines topics from a wide range of disciplines, such as Docetaxel and Hazard ratio.
His work carried out in the field of Lung cancer brings together such families of science as Adverse effect, Cancer research, Carcinoma and Adenocarcinoma.
The study incorporates disciplines such as Regimen, Clinical endpoint and non-small cell lung cancer in addition to Chemotherapy.
His Epidermal growth factor receptor research integrates issues from Tyrosine kinase and Tyrosine-kinase inhibitor.
He most often published in these fields:
- Internal medicine (66.54%)
- Oncology (54.65%)
- Lung cancer (41.82%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (66.54%)
- Oncology (54.65%)
- Lung cancer (41.82%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer research and Epidermal growth factor receptor.
In his study, Neutropenia is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine.
The various areas that Keunchil Park examines in his Oncology study include Clinical trial and Hazard ratio.
His Lung cancer study incorporates themes from Immunotherapy, Clinical endpoint and Adenocarcinoma.
Keunchil Park has included themes like Cancer, DNA damage, Mutation, Immune system and Small molecule in his Cancer research study.
His Chemotherapy study is associated with Surgery.
Between 2017 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (499 citations)
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study (172 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Lung cancer, Cancer research and In patient.
As part of his studies on Internal medicine, Keunchil Park frequently links adjacent subjects like Gastroenterology.
His Oncology research incorporates elements of Progressive disease, Cohort and Epidermal growth factor receptor.
His Lung cancer research includes themes of Adverse effect, Disease and Adenocarcinoma.
His Cancer research research is multidisciplinary, relying on both Base excision repair, EGFR Tyrosine Kinase Inhibitors, Mutation, Bispecific antibody and MAPK/ERK pathway.
His work deals with themes such as Pembrolizumab and Discontinuation, which intersect with Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
